6-Chloropurine-9-riboside | CAS:2004-06-0

We serve 6-Chloropurine-9-riboside CAS:2004-06-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
6-Chloropurine-9-riboside

Chemical Name:6-Chloropurine-9-riboside
CAS.NO:2004-06-0
Synonyms:6-CHLOROINOSINE
6-Chloro-6-deoxyinosine
6-Chloropurine riboside
6-Chloropurine ribos
6-CHLOROPURINE NUCLEOSIDE
Molecular Formula:C10H11ClN4O5
Molecular Weight:302.67100
 
Physical and Chemical Properties:
Density:2.03
Melting point:161-163ºC
Boiling point:614.8ºC
Flash point:325.6ºC
Index of Refraction:1.846
 
Specification:
Appearance:White or light yellow crystalline powder
Assay(HPLC):≥98.0%
Loss on drying:≤0.5%
Residue on ignition:≤0.1%
Heavy metal:≤10ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:6-CHLOROPURINE RIBOSIDE acts as a reactant in the synthesis of isozyme-specific enzyme inhibitors as well as in the preparation of dog coronary artery receptor agonists.



Contact us for information like 6-Chloropurine-9-riboside chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-CHLOROPURINE NUCLEOSIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-CHLOROINOSINE Use and application,6-Chloropurine ribos technical grade,usp/ep/jp grade.


Related News: In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.4-Fluoro-3-nitrobenzoic acid manufacturer We are pleased that he is doing well,” said BPHC Executive Director Rita Nieves. “Right now, we are not asking Boston residents to do anything differently.2,3-Difluoro-5-chloropyridine supplier The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.(3-Chloro-5-cyanophenyl)boronic acid vendor Airlines operating in the United States will be required to ask all passengers booked on flights from outside the US if they’ve been to mainland China in last 14 days.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.